Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2012
04/05/2012WO2012043633A1 Inhibitor of expression of dominantly mutated gene
04/05/2012WO2012043577A1 Reversing agent for anticoagulants
04/05/2012WO2012043549A1 Arctigenin-containing bardanae fructus extract and method for producing same
04/05/2012WO2012043533A1 Antihuman ccr7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
04/05/2012WO2012043505A1 Novel piperidine derivative and pharmaceutical containing same
04/05/2012WO2012043481A1 Composition containing 2-acyl-lysophosphatidylserine and method for producing same
04/05/2012WO2012043445A1 Cyclohexane derivative compound
04/05/2012WO2012043393A1 Emulsion composition
04/05/2012WO2012043185A1 Composition for inhibiting il-8 expression
04/05/2012WO2012043052A1 Surgical cleaning solution
04/05/2012WO2012042951A1 Atorbastatin-containing medicinal tablet
04/05/2012WO2012042915A1 Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
04/05/2012WO2012042502A1 Diazaridine derivatives for treating metal disorders
04/05/2012WO2012042482A1 Process for the synthesis of funicone analogues
04/05/2012WO2012042433A1 N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
04/05/2012WO2012042421A1 Method of treating abnormal cell growth
04/05/2012WO2012042357A1 Swinglea glutinosa leaves derived material in combination with avermectins for control of acari
04/05/2012WO2012042314A1 Treatment of tinnitus and related auditory dysfunctions
04/05/2012WO2012042265A1 Novel acridine derivatives
04/05/2012WO2012042224A2 Pharmaceutical composition
04/05/2012WO2012042197A2 Low dose pharmaceutical composition
04/05/2012WO2012042128A1 Pharmaceutical composition comprising memantine and vitamin d for treating alzheimer's disease
04/05/2012WO2012042123A1 Biotinylated polysaccharides having an antithrombotic activity and improved metabolic stability
04/05/2012WO2012042080A1 Method for producing oils and fats with a high antioxidant content
04/05/2012WO2012042078A1 Chromene derivatives
04/05/2012WO2012042072A1 Topical amphotericin b formulations and production method thereof
04/05/2012WO2012042042A1 Selective lsd1 and dual lsd1/mao-b inhibitors for modulating diseases associated with alterations in protein conformation
04/05/2012WO2012041987A1 Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
04/05/2012WO2012041966A1 Ovule for vaginal administration of arasertaconazole
04/05/2012WO2012041959A1 Treatment of b-cell lymphoma with microrna
04/05/2012WO2012041934A1 Polysubstituted 2-aminoimidazoles for controlling biofilms and process for their production
04/05/2012WO2012041898A1 Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
04/05/2012WO2012041873A1 N-heteroaryl compounds
04/05/2012WO2012041872A1 N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
04/05/2012WO2012041860A1 Benzazole derivatives as histamine h4 receptor ligands
04/05/2012WO2012041817A1 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as ccr2 receptor antagonists
04/05/2012WO2012041814A1 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
04/05/2012WO2012041771A1 Combination therapy for treating hcv infection
04/05/2012WO2012041717A1 Use of magnesium stearate in dry powder formulations for inhalation
04/05/2012WO2012041524A1 Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
04/05/2012WO2012041493A1 Aminoquinolinium salts, methods of their production and their use as active agents for biotechnological and medical applications against binary toxins
04/05/2012WO2012041488A1 Dry processing of atazanavir
04/05/2012WO2012041476A1 Pyridine and isoquinoline derivatives as syk- and jak-kinase inhibitors
04/05/2012WO2012041435A1 Phenylquinazoline derivatives
04/05/2012WO2012041334A1 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
04/05/2012WO2012041258A1 Compositions and methods for treating hypertension using eprosartan and amlodipine
04/05/2012WO2012041253A1 Compounds for increase of hdl-c level and uses thereof
04/05/2012WO2012041227A1 Tetracyclic heterocycle compounds for treating hepatitis c viral infection
04/05/2012WO2012041158A1 Tricyclic compound, preparation method and pharmaceutical use thereof
04/05/2012WO2012041124A1 Azabicyclo octane derivatives, preparation process and pharmaceutical use thereof
04/05/2012WO2012041031A1 Compound composition for inhalation used for treating asthma
04/05/2012WO2012041014A1 Tetracyclic indole derivatives for treating hepatitis c virus infection
04/05/2012WO2012041013A1 Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same
04/05/2012WO2012040938A1 Use of fucoxanthin in the preparation of product having neuroprotective effect associated with neurodegenerative disorder and improving memory
04/05/2012WO2012040924A1 Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
04/05/2012WO2012040923A1 Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
04/05/2012WO2012040919A1 Use of baicalein in manufacturing medicament for preventing and treating parkinson's disease
04/05/2012WO2012040841A1 Use of nigericin to treat and prevent vaccinia virus infections
04/05/2012WO2012024419A3 Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
04/05/2012WO2012020272A3 New salts, polymorphs and solvates of febuxostat
04/05/2012WO2012020131A3 Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
04/05/2012WO2012018854A8 Pactamycin analogs and methods of use
04/05/2012WO2012018810A9 St-246 liquid formulations and methods
04/05/2012WO2012017239A3 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
04/05/2012WO2012012498A9 Use of trp channel agonists to treat infections
04/05/2012WO2012012147A3 Methods and compositions for treatment of multiple sclerosis
04/05/2012WO2012009315A3 Bovine milk oligosaccharides
04/05/2012WO2012006551A3 Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
04/05/2012WO2012006398A3 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
04/05/2012WO2012005885A3 Nutraceutical product containing anatabine and yerba maté
04/05/2012WO2012005536A3 Pharmaceutical compositions including carbamoyloxy arylalkanoyl arylpiperazine compound
04/05/2012WO2012000971A3 Compositions with a high active ingredient fraction of a mixture of chondroitin sulphate and glucosamine
04/05/2012WO2011163614A3 Methods of treatment for esophageal inflammation
04/05/2012WO2011160974A3 Statin derivates and intermediates for their production
04/05/2012WO2011159840A3 Phenylthioacetate compounds, compositions and methods of use
04/05/2012WO2011159550A3 Lysophosphatidic acid receptor antagonist and uses thereof
04/05/2012WO2011156329A3 Methods of treating pain and morphine tolerance via modulation of hedgehog signalling pathway
04/05/2012WO2011156321A9 Furanyl compounds and the use thereof
04/05/2012WO2011153514A9 The use of inhibitors of bruton's tyrosine kinase (btk)
04/05/2012WO2011152805A3 Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid
04/05/2012WO2011150299A3 Treatment of myocardial infarction and vascular injury with netrin-1
04/05/2012WO2011150007A3 Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
04/05/2012WO2011150005A3 Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
04/05/2012WO2011149993A3 SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
04/05/2012WO2011146918A3 Macrocyclic compounds and methods of treatment
04/05/2012WO2011146674A3 Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11
04/05/2012WO2011146594A3 Mtor selective kinase inhibitors
04/05/2012WO2011143660A3 Compositions and methods for treating leukemia
04/05/2012WO2011143444A3 Diphenylbutypiperidine autophagy inducers
04/05/2012WO2011143201A3 Ratiometric combinatorial drug delivery
04/05/2012WO2011141488A3 Pharmaceutical compositions comprising hydromorphone and naloxone
04/05/2012WO2011141483A3 Stable pharmaceutical formulations containing an antihistaminic
04/05/2012WO2011140310A3 Povidone-iodine topical composition
04/05/2012WO2011140285A3 Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
04/05/2012WO2011139899A3 Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
04/05/2012WO2011139867A3 Method of treating brain cancer
04/05/2012WO2011139832A3 Method for treating mycobacterial infections
04/05/2012WO2011139752A3 Preparation of polypeptides and salts thereof
04/05/2012WO2011139343A3 Amino acid linked peg-lipid conjugates
04/05/2012WO2011137331A3 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
1 ... 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 ... 7860